In a dramatic turn of events, genetic testing company 23andMe’s stock (NASDAQ: ME) has witnessed a sharp plunge in its stock price following alarming news of its CEO’s resignation and speculation surrounding the company’s financial health. As investor sentiment nosedives, concerns about potential bankruptcy and leadership instability have taken center stage. What Occurred? On March…